Here’s what you should know:
1. Committee members had concerns on a number of issues including:
- A lack of data on how the drug affects the elderly
- Inadequate plans to prevent abuse and misuse
- The inflexibility of a single-dose product
2. Boston-based Brigham Women’s Hospital Pain Trials Center Director Edward Michna, MD, said, “This drug, while a good idea, wasn’t really well thought-out in terms of how we use these drugs clinically.”
3. If the drug is approved by the FDA, it would be the first to include antiemetic properties.
4. The drug is intended to provide short-term management of acute pain, while preventing opioid-induced nausea and vomiting.
For more information on the drug, click here.
More articles on anesthesia:
2 ASCs & outpatient facilities achieving certification and accreditation — January 2018
The opioid crisis cost $1T+ since 2001, may cost additional $500B by 2020: 6 takeaways
How the right technology platform can support GI practice growth and patient experience
